Trade BridgeBio Pharma, Inc. - BBIO CFD
Add to favourite- Summary
- Historical Data
Spread | 0.13 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 24.28 |
Open | 24.29 |
1-Year Change | 66.26% |
Day's Range | 24.29 - 24.87 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 25, 2024 | 24.28 | 0.03 | 0.12% | 24.25 | 24.44 | 23.63 |
Apr 24, 2024 | 24.97 | -0.28 | -1.11% | 25.25 | 25.64 | 24.34 |
Apr 23, 2024 | 25.39 | 0.66 | 2.67% | 24.73 | 26.20 | 24.73 |
Apr 22, 2024 | 25.01 | 0.12 | 0.48% | 24.89 | 25.46 | 24.07 |
Apr 19, 2024 | 24.68 | -0.04 | -0.16% | 24.72 | 25.23 | 24.22 |
Apr 18, 2024 | 24.91 | 0.15 | 0.61% | 24.76 | 25.46 | 24.70 |
Apr 17, 2024 | 24.93 | -0.35 | -1.38% | 25.28 | 25.56 | 24.69 |
Apr 16, 2024 | 25.21 | -0.04 | -0.16% | 25.25 | 25.86 | 25.14 |
Apr 15, 2024 | 25.73 | -0.74 | -2.80% | 26.47 | 26.61 | 25.64 |
Apr 12, 2024 | 26.78 | -0.85 | -3.08% | 27.63 | 27.91 | 26.31 |
Apr 11, 2024 | 28.32 | 1.02 | 3.74% | 27.30 | 28.70 | 26.80 |
Apr 10, 2024 | 27.26 | 0.21 | 0.78% | 27.05 | 27.43 | 26.67 |
Apr 9, 2024 | 28.40 | 0.18 | 0.64% | 28.22 | 28.58 | 27.75 |
Apr 8, 2024 | 28.22 | -0.04 | -0.14% | 28.26 | 28.39 | 27.78 |
Apr 5, 2024 | 28.07 | 0.17 | 0.61% | 27.90 | 28.70 | 27.57 |
Apr 4, 2024 | 28.10 | -1.20 | -4.10% | 29.30 | 29.50 | 28.05 |
Apr 3, 2024 | 29.17 | 0.92 | 3.26% | 28.25 | 29.26 | 28.18 |
Apr 2, 2024 | 28.75 | -0.53 | -1.81% | 29.28 | 29.29 | 28.52 |
Apr 1, 2024 | 29.92 | -0.78 | -2.54% | 30.70 | 30.70 | 29.60 |
Mar 28, 2024 | 30.84 | 0.12 | 0.39% | 30.72 | 31.12 | 30.29 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
BridgeBio Pharma, Inc. Company profile
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.; the University of California, San Diego; Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; UC San Francisco; the Canadian Glycomics Network (GlycoNet); the University of California; Columbia University; Mount Sinai; and Helsinn Group, as well as a clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398. It also has a research collaboration and option agreement with Unnatural Products Inc. to target rare diseases with potential oncology applications. The company was founded in 2015 and is headquartered in Palo Alto, California.Industry: | Biopharmaceuticals |
3160 Porter Dr.
Suite 250
PALO ALTO
CALIFORNIA 94304
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com